Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2021 | Patient segmentation for targeted therapy in myeloma

Gareth Morgan, MD, PhD, FRCP, FRCPath, and Faith Davies, MBBCh, MRCP, MD, FRCPath, both of NYU Langone Health, New York, NY, discuss their debate on patient segmentation for the delivery of targeted therapy for myeloma at the IMW 2021 meeting. Prof. Davies explains that although patient subgroups responding poorly to treatment have been identified, patient stratification needs to be refined further, taking into consideration 17p and 1q chromosome gain/amplification, as well as mutational status, in order to better strategize clinical trials. Prof. Morgan comments that the debate is not about when stratification should be carried out, but it is a question of how exactly we should proceed. Prof. Davies and Prof. Morgan also discuss the role of bispecific antibodies and chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of multiple myeloma, and how these are impacting the field. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.